A randomised, double-blind, placebo-controlled trial assessing the efficacy and safety of dutasteride (Avodart) 0.5 mg in extending the time to PSA [prostate specific antigen] doubling in men with prostate cancer and biochemical failure (PSA increase) after radical therapy with curative intent (ARTS-Avodart After Radical Therapy for Prostate Cancer Study).

Trial Profile

A randomised, double-blind, placebo-controlled trial assessing the efficacy and safety of dutasteride (Avodart) 0.5 mg in extending the time to PSA [prostate specific antigen] doubling in men with prostate cancer and biochemical failure (PSA increase) after radical therapy with curative intent (ARTS-Avodart After Radical Therapy for Prostate Cancer Study).

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ARTS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 May 2013 Primary endpoint 'Prostate-specific-antigen-doubling-time' has been met.
    • 12 May 2012 This trial is recruiting in France, Spain and has been discontinued in Lithuania, Latvia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top